Business Description

TransMedics Group Inc. is a U.S.-based health care company founded in 2008 that markets the innovative Organ Care System (OCS), a portable organ perfusion system designed to improve transplant outcomes. The company earns revenue from hardware sales and recurring consumable services provided to hospitals and transplant centers. Led by CEO Dr. Christopher J. Love, TransMedics has captured an estimated 15-20% share of the U.S. organ perfusion market while expanding its clinical footprint. Its future initiatives include launching additional organ modules and entering international markets to drive further growth.

Everything on TransMedics Group Inc.

Revenue (FY2025) $605M
YoY growth +37.1%
Operating margin 17.9%
Direction Expanding
Gross margin 59.9%
Net margin 31.4%

Earnings Transcripts

View all transcripts ↗

Leadership & board

View leadership ↗
Waleed H. Hassanein, M.D. — Founder, President and Chief Executive Officer; Director View full profile ↗ James R. Tobin — Director; Chairperson of the Board View full profile ↗ Edward M. Basile — Director; Chairperson of the Nominating and Corporate Governance Committee View full profile ↗ Thomas J. Gunderson — Director; Chairperson of the Compensation Committee View full profile ↗ Edwin M. Kania, Jr. — Director View full profile ↗ Stephanie Lovell — Director View full profile ↗ Merilee Raines — Director; Chairperson of the Audit Committee View full profile ↗ David Weill, M.D. — Director View full profile ↗ Gerardo Hernandez — Chief Financial Officer and Treasurer View full profile ↗ Giovanni Cecere — Chief Commercial Officer View full profile ↗ Nicholas Corcoran — Senior Vice President of Supply Chain and Operations View full profile ↗ Matthew Forsyth — Senior Vice President, General Counsel and Corporate Secretary View full profile ↗ Tamer Khayal, M.D. — Senior Vice President of International (former Chief Commercial Officer) View full profile ↗ Anil Ranganath — Former Senior Vice President, General Counsel and Corporate Secretary View full profile ↗ Stephen Gordon — Former Chief Financial Officer, Treasurer and Secretary View full profile ↗ Miriam Provost, Ph.D. — Vice President of U.S. Regulatory and FDA Relations View full profile ↗ Laura Damme — Former Executive Officer (title not disclosed in filings) View full profile ↗

Share Repurchase Program

TransMedics has no share-repurchase program; Item 5 of the 10-K states the Company did not purchase any of its registered equity securities during the period from September 30, 2025 to December 31, 2025.

Named Competitors

OrganOx LimitedXVIVO Perfusion ABParagonix Technologies, Inc.

Customer Concentration

For the years ended December 31, 2025, 2024 and 2023, no customer accounted for more than 10% of revenue, and as of December 31, 2025 and 2024, no customer accounted for more than 10% of accounts receivable.

Recent SEC Filings

2026-05-21 Shareholder vote results View filing ↗
2026-05-05 Reported quarterly results View filing ↗
2026-02-27 Reported quarterly results View filing ↗
2026-02-24 Reported quarterly results View filing ↗
2026-02-04 Leadership change (directors/officers) View filing ↗
2026-01-12 Entered a material agreement (+1 more) View filing ↗
2025-10-29 Reported quarterly results View filing ↗
2025-10-06 Completed an acquisition or disposition View filing ↗
2025-07-30 Reported quarterly results View filing ↗
2025-05-23 Shareholder vote results View filing ↗
2025-05-08 Reported quarterly results View filing ↗
2025-02-27 Reported quarterly results View filing ↗

More Companies

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.